Cargando…

PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections

PURPOSE: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections given upon reactivation of the disease in eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective study of naïve nAMD cases with more than one year of follow-up, treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Banaee, Touka, Alwan, Shadan, Kellogg, Clint, Kornblau, Ilyse, El-Annan, Jaafar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PUBLISHED BY KNOWLEDGE E 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126743/
https://www.ncbi.nlm.nih.gov/pubmed/34055255
http://dx.doi.org/10.18502/jovr.v16i2.9081
_version_ 1783693828050386944
author Banaee, Touka
Alwan, Shadan
Kellogg, Clint
Kornblau, Ilyse
El-Annan, Jaafar
author_facet Banaee, Touka
Alwan, Shadan
Kellogg, Clint
Kornblau, Ilyse
El-Annan, Jaafar
author_sort Banaee, Touka
collection PubMed
description PURPOSE: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections given upon reactivation of the disease in eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective study of naïve nAMD cases with more than one year of follow-up, treated with a protocol of cycles of three monthly injections of anti-VEGF drugs upon reactivation. Visual acuity (VA) and central macular thickness (CMT) are the main outcome measures. RESULTS: Twenty-six patients with a mean age of 78.15 [Formula: see text] 9.29 years (57.7% female) were included. The mean follow-up was 30.89 [Formula: see text] 6.95 months. Treatment started with bevacizumab in all patients but in six patients was switched to aflibercept due to inadequate response to intravitreal bevacizumab injection. The mean VA at baseline and at 12 and 24 months was 53.87 [Formula: see text] 21.84, 60.54 [Formula: see text] 21.13, and 53.68 [Formula: see text] 27.16 ETDRS letters, respectively. Patients gained a mean of 6.67 [Formula: see text] 13.7 (p = 0.013, 95% CI= 0.60 to 12.65) and 0.77 [Formula: see text] 15.21 (p = 0.4, 95% CI: –5.65 to 7.2) letters at 12 and 24 months. CMT at baseline, 12, and 24 months was 403.55 [Formula: see text] 147.59, 323.95 [Formula: see text] 79.58, and 298.59 [Formula: see text] 77.161 µm, respectively. The number of injections in the first and second years were 7.65 [Formula: see text] 2.64 and 5.52 [Formula: see text] 3.01, respectively. Three eyes (12.5%) lost [Formula: see text] 15 letters at 24 months. CONCLUSION: This protocol can stabilize or improve vision in 87.5% of nAMD patients and can reduce the number of visits.
format Online
Article
Text
id pubmed-8126743
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher PUBLISHED BY KNOWLEDGE E
record_format MEDLINE/PubMed
spelling pubmed-81267432021-05-27 PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections Banaee, Touka Alwan, Shadan Kellogg, Clint Kornblau, Ilyse El-Annan, Jaafar J Ophthalmic Vis Res Original Article PURPOSE: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections given upon reactivation of the disease in eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective study of naïve nAMD cases with more than one year of follow-up, treated with a protocol of cycles of three monthly injections of anti-VEGF drugs upon reactivation. Visual acuity (VA) and central macular thickness (CMT) are the main outcome measures. RESULTS: Twenty-six patients with a mean age of 78.15 [Formula: see text] 9.29 years (57.7% female) were included. The mean follow-up was 30.89 [Formula: see text] 6.95 months. Treatment started with bevacizumab in all patients but in six patients was switched to aflibercept due to inadequate response to intravitreal bevacizumab injection. The mean VA at baseline and at 12 and 24 months was 53.87 [Formula: see text] 21.84, 60.54 [Formula: see text] 21.13, and 53.68 [Formula: see text] 27.16 ETDRS letters, respectively. Patients gained a mean of 6.67 [Formula: see text] 13.7 (p = 0.013, 95% CI= 0.60 to 12.65) and 0.77 [Formula: see text] 15.21 (p = 0.4, 95% CI: –5.65 to 7.2) letters at 12 and 24 months. CMT at baseline, 12, and 24 months was 403.55 [Formula: see text] 147.59, 323.95 [Formula: see text] 79.58, and 298.59 [Formula: see text] 77.161 µm, respectively. The number of injections in the first and second years were 7.65 [Formula: see text] 2.64 and 5.52 [Formula: see text] 3.01, respectively. Three eyes (12.5%) lost [Formula: see text] 15 letters at 24 months. CONCLUSION: This protocol can stabilize or improve vision in 87.5% of nAMD patients and can reduce the number of visits. PUBLISHED BY KNOWLEDGE E 2021-04-29 /pmc/articles/PMC8126743/ /pubmed/34055255 http://dx.doi.org/10.18502/jovr.v16i2.9081 Text en Copyright © 2021 Banaee et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Banaee, Touka
Alwan, Shadan
Kellogg, Clint
Kornblau, Ilyse
El-Annan, Jaafar
PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title_full PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title_fullStr PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title_full_unstemmed PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title_short PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections
title_sort prn treatment of neovascular amd with cycles of three monthly injections
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126743/
https://www.ncbi.nlm.nih.gov/pubmed/34055255
http://dx.doi.org/10.18502/jovr.v16i2.9081
work_keys_str_mv AT banaeetouka prntreatmentofneovascularamdwithcyclesofthreemonthlyinjections
AT alwanshadan prntreatmentofneovascularamdwithcyclesofthreemonthlyinjections
AT kelloggclint prntreatmentofneovascularamdwithcyclesofthreemonthlyinjections
AT kornblauilyse prntreatmentofneovascularamdwithcyclesofthreemonthlyinjections
AT elannanjaafar prntreatmentofneovascularamdwithcyclesofthreemonthlyinjections